Zimmer Biomet Holdings (0QQD) Stock Overview
Operates as a medical technology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
0QQD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Zimmer Biomet Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$77.38 |
| 52 Week High | US$77.38 |
| 52 Week Low | US$77.38 |
| Beta | 0.68 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -16.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QQD | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 3.2% | 2.2% |
| 1Y | n/a | 13.4% | 13.4% |
Return vs Industry: Insufficient data to determine how 0QQD performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how 0QQD performed against the UK Market.
Price Volatility
| 0QQD volatility | |
|---|---|
| 0QQD Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: 0QQD's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine 0QQD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1927 | 17,000 | Ivan Tornos | www.zimmerbiomet.com |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products.
Zimmer Biomet Holdings, Inc. Fundamentals Summary
| 0QQD fundamental statistics | |
|---|---|
| Market cap | CHF 16.72b |
| Earnings (TTM) | CHF 657.38m |
| Revenue (TTM) | CHF 6.25b |
Is 0QQD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QQD income statement (TTM) | |
|---|---|
| Revenue | US$7.83b |
| Cost of Revenue | US$2.25b |
| Gross Profit | US$5.58b |
| Other Expenses | US$4.76b |
| Earnings | US$823.50m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.16 |
| Gross Margin | 71.25% |
| Net Profit Margin | 10.51% |
| Debt/Equity Ratio | 61.6% |
How did 0QQD perform over the long term?
See historical performance and comparisonDividends
Does 0QQD pay a reliable dividends?
See 0QQD dividend history and benchmarks| Zimmer Biomet Holdings dividend dates | |
|---|---|
| Ex Dividend Date | Sep 30 2025 |
| Dividend Pay Date | Oct 31 2025 |
| Days until Ex dividend | 5 days |
| Days until Dividend pay date | 26 days |
Does 0QQD pay a reliable dividends?
See 0QQD dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/07 22:09 |
| End of Day Share Price | 2025/06/11 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zimmer Biomet Holdings, Inc. is covered by 62 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Stephan Gasteyger | Atlantic Equities LLP |
| Jeffrey Johnson | Baird |